{
  "id": "5e2900368b3851296d000001",
  "type": "summary",
  "question": "Describe the mechanism of action of a drug Elagolix.",
  "ideal_answer": "Elagolix is a novel, orally active, non-peptide, competitive gonadotropin-releasing hormone (GnRH) receptor antagonist. It is in development for the management of endometriosis with associated pain and heavy menstrual bleeding due to uterine fibroids.",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/30194661",
    "http://www.ncbi.nlm.nih.gov/pubmed/29889764",
    "http://www.ncbi.nlm.nih.gov/pubmed/29335207",
    "http://www.ncbi.nlm.nih.gov/pubmed/28737050",
    "http://www.ncbi.nlm.nih.gov/pubmed/28323948",
    "http://www.ncbi.nlm.nih.gov/pubmed/29946962",
    "http://www.ncbi.nlm.nih.gov/pubmed/19033369",
    "http://www.ncbi.nlm.nih.gov/pubmed/28525302",
    "http://www.ncbi.nlm.nih.gov/pubmed/29476499",
    "http://www.ncbi.nlm.nih.gov/pubmed/31749075",
    "http://www.ncbi.nlm.nih.gov/pubmed/28255765",
    "http://www.ncbi.nlm.nih.gov/pubmed/30303923",
    "http://www.ncbi.nlm.nih.gov/pubmed/30320043",
    "http://www.ncbi.nlm.nih.gov/pubmed/25249568",
    "http://www.ncbi.nlm.nih.gov/pubmed/30551159"
  ],
  "snippets": [
    {
      "text": "Compound 12c showed potent and prolonged LH suppression after a single dose was orally administered in castrated monkeys compared to a known antagonist, Elagolix. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29335207",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "INTRODUCTION: Elagolix is a novel, orally active, non-peptide, competitive gonadotropin-releasing hormone (GnRH) receptor antagonist in development for the management of endometriosis with associated pain and heavy menstrual bleeding due to uterine fibroids. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29476499",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "OBJECTIVE: To evaluate the efficacy and safety of elagolix, an oral, nonpeptide gonadotropin-releasing hormone antagonist, over 12 months in women with endometriosis-associated pain.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29889764",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Phase III trials on elagolix, a new oral GnRH antagonist but non-inferiority RCT data are required to compare elagolix with first-line therapies for endometriosis.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29946962",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Elagolix (ORILISSA\u2122), an orally bioavailable, second-generation, non-peptide gonadotropin-releasing hormone (GnRH) receptor antagonist, is being developed AbbVie and Neurocrine Biosciences for the treatment of reproductive hormone-dependent disorders in women.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30194661",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "OBJECTIVE: To evaluate elagolix, an oral gonadotropin-releasing hormone receptor antagonist, alone or with add-back therapy, in premenopausal women with heavy menstrual bleeding (greater than 80 mL per month) associated with uterine leiomyomas.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30303923",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Research development of a new GnRH antagonist (Elagolix) for the treatment of endometriosis: a review of the literature.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28255765",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Elagolix, an orally active non-peptidic GnRH antagonist, has been approved by the Food and Drug Administration for the management of moderate to severe pain associated with endometriosis.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30551159",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Elagolix is a novel, orally available nonpeptide GnRH antagonist.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/19033369",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Treatment of Endometriosis-Associated Pain with Elagolix, an Oral GnRH Antagonist.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28525302",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Elagolix, an Oral GnRH Antagonist for Endometriosis-Associated Pain: A Randomized Controlled Study.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30320043",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "In addition to already established medications, a new GnRH antagonist, elagolix, is in development.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28737050",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Clinical Pharmacology of Elagolix: An Oral Gonadotropin-Releasing Hormone Receptor Antagonist for Endometriosis.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31749075",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Context: Elagolix is a nonpeptide, oral gonadotropin-releasing hormone (GnRH) antagonist being developed for sex-hormone-dependent diseases in women.Objective: We evaluated the pharmacokinetics and pharmacodynamics of elagolix.Design, Setting, and Participants: This study was a randomized, double-blind, placebo-controlled, multiple-ascending dose study in 45 healthy premenopausal women at a research unit.Interventions: Elagolix [150 mg once daily or 100, 200, 300, or 400 mg twice daily (BID)] or placebo was administered for 21 days.Main Outcome Measures: Main outcome measures were elagolix pharmacokinetics, suppression of gonadotropics [follicle-stimulating hormone (FSH), luteinizing hormone (LH)] and ovarian hormones [estradiol (E2), progesterone (P)], and adverse events.Results: Elagolix was rapidly absorbed after oral dosing, reaching maximum concentrations at 1.0 to 1.5 hours, with a half-life of 4 to 6 hours.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28323948",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Elagolix, an oral GnRH antagonist, versus subcutaneous depot medroxyprogesterone acetate for the treatment of endometriosis: effects on bone mineral density.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/25249568",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "While elagolix may have an advantage over established GnRH agonists, in that it does not lead to a 'flare-up' effect, it too, takes a toll on bone mineral density.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28737050",
      "beginSection": "abstract",
      "endSection": "abstract"
    }
  ],
  "concepts": []
}